Author's posts
340B showdown: Big pharma, hospitals squaring off in lobbying fight
Hospitals have adopted a take-no-prisoners approach in the fight with Big Pharma over the 340B drug discount program. Can this strategy hold as Congress, oversight agencies, the courts and the Trump administration ratchet up scrutiny of the program?
Health systems look to mend fractured consumer experience
The healthcare industry has largely been unable to meet consumers’ expectations, but a group of health system and physician group executives shared how they plan to change that at Modern Healthcare’s Consumerism Symposium.
Commentary: Transformation can put hospitals at the center of their communities
The major healthcare innovation story is occurring across the country in cities and small towns, where local hospitals and health systems are now centers of transformational change.
Medical students play a high-stakes game to match into residency programs
Physicians are beginning to question how fair the match program is and whether it meets the needs of doctors-in-training and patients.
Week Ahead: Earnings season to be interrupted by MIPS oversight
Heavy hitters Anthem, HCA and UHS will release their Q2 earnings. Meanwhile, a House panel will delve into the MIPS program.
Editorial: Healthcare support jobs should be well-paid jobs
Growing pay inequality is a huge problem in healthcare. It’s going to take a conscious commitment by healthcare’s top leaders, sustained over many years, to turn the industry’s critical support jobs into good jobs.
Physician pay increases may be slowing
Physician compensation rose only slightly for most medical specialties in 2017 indicating the steady growth in pay seen over the past several years may have started to slow.
How to limit drug prices
HHS received over 3,000 comments on the Trump administration’s Blueprint to Lower Drug Prices, which was released in May. Hospitals, health insurers and drugmakers had plenty to say on how to address soaring drug prices
LifePoint’s share price spikes 40% on report of buyout talks
LifePoint Health’s share price jumped 40% in after-hours trading Friday on news the company is in acquisition talks with a private equity firm.
Pfizer’s biosimilar for chemo patients OK’d to vie against Amgen’s Neupogen
Nivestym is not the first biosimilar of Neupogen, which helps chemotherapy patients recover, but it reflects the Food and Drug Administration’s emphasis on bringing more biosimilars to market.
